Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.

Mega Genomics Limited
美因基因有限公司*
(Incorporated in the Cayman Islands with limited liability)
(Stock code: 6667)

DELAY IN DESPATCH OF CIRCULAR CONTINUING CONNECTED TRANSACTIONS PROPOSED REVISION OF THE 2026 ANNUAL CAP UNDER THE 2024 MEINIAN FRAMEWORK AGREEMENT

Reference is made to the announcement of Mega Genomics Limited (the "**Company**") dated 29 October 2026 (the "**Announcement**") in relation to the proposed revision of the 2026 annual cap under the 2024 Meinian Framework Agreement. Unless otherwise defined, capitalised terms used in this announcement shall have the same meanings as those defined in the Announcement.

As disclosed in the Announcement, a circular (the "**Circular**") containing, among other things, (i) further details of the proposed revision of the 2026 annual cap; (ii) the recommendation of the Independent Board Committee; (iii) the advice of the Independent Financial Adviser; and (iv) the notice convening the EGM, was expected to be despatched to the Shareholders on or before 9 November 2026.

As additional time is required to prepare and finalise certain information for inclusion in the Circular, the Circular is now expected to be despatched on or before 13 November 2026.

By Order of the Board
Mega Genomics Limited
LIN Lin
Executive Director and Chairperson

Hong Kong, 9 November 2026

As of the date of this announcement, the executive Directors are Dr. Yu Rong, Ms. Lin Lin and Ms. Jiang Jing; the non-executive Director is Ms. Guo Meiling; and the independent non-executive Directors are Dr. Zhang Ying, Mr. Jia Qingfeng and Dr. Xie Dan.

* *For identification purpose only*